Bronchopulmonary Dysplasia Epidemiology Forecast

DelveInsight’s ‘Bronchopulmonary Dysplasia- Epidemiology Forecast–2032’ report delivers an in-depth understanding of the Bronchopulmonary Dysplasia, historical and forecasted epidemiology as well as the Bronchopulmonary Dysplasia trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan. 

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Bronchopulmonary Dysplasia Disease Understanding

Bronchopulmonary Dysplasia is a chronic respiratory disease that often occurs in low-weight or premature infants who have received supplemental oxygen or have spent long periods on a breathing machine (mechanical ventilation), such as infants with acute respiratory distress syndrome. Bronchopulmonary Dysplasia also occurs in older infants who experience abnormal lung development or those that have an antenatal infection or placental abnormalities (like preeclampsia) or chorioamnionitis. Babies are not born with Bronchopulmonary Dysplasia, also referred to as chronic lung disease of prematurity, it is associated with how a baby’s lung tissue develops.

 

The risk of developing Bronchopulmonary Dysplasia increases the earlier a baby is born and the lower the birth weight. Affected infants have rapid, labored breathing, tachypnea, cyanosis, feeding difficulties, and recurrent lung infection. The pathogenesis of Bronchopulmonary Dysplasia remains complex and poorly understood. It results from various factors that injure small airways and can interfere with alveolarization, leading to alveolar simplification with a reduction in the overall surface area for gas exchange. The developing pulmonary microvasculature is also injured. Damage to the lung during a critical stage of lung growth results in clinically significant pulmonary dysfunction

 

Bronchopulmonary Dysplasia is divided into three severity grades (mild, moderate, or severe) based on respiratory support needs at 36 weeks postmenstrual age (PMA). The exact, underlying mechanisms that cause classic or new Bronchopulmonary Dysplasia are complex and not fully understood. The causes of Bronchopulmonary Dysplasia in one infant may be different from the causes in another. Most likely, multiple different environmental and genetic factors all play a role in the development of the disorder.

 

The cases of Bronchopulmonary Dysplasia have been increasing, most likely because of modern advances in medicine, which have enabled doctors to keep more low birth weight, premature babies alive than in the past. 

 

Bronchopulmonary Dysplasia Diagnosis 

Infants with Bronchopulmonary Dysplasia show substantial heterogeneity in clinical presentation and long-term outcomes. The manner and precision with which Bronchopulmonary Dysplasia is defined have far-reaching consequences for translational and clinical research.

 

Diagnosis is done based upon identification of characteristic symptoms, detailed patient history, thorough clinical evaluation, and a variety of specialized tests, including blood tests, chest x-rays, and echocardiograms. Many infants now, diagnosed with Bronchopulmonary Dysplasia, are born at an earlier gestational age than before. These cases are sometimes referred to as “new Bronchopulmonary Dysplasia.” They generally have less inflammation and scarring than classic Bronchopulmonary Dysplasia.

Continued in the report….. 

Bronchopulmonary Dysplasia Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total incident cases of Bronchopulmonary Dysplasia, weight-specific cases of Bronchopulmonary Dysplasia, and severity-specific cases of Bronchopulmonary Dysplasia scenario of Bronchopulmonary Dysplasia in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Bronchopulmonary Dysplasia Detailed Epidemiology Segmentation

  • Total incident cases of Bronchopulmonary Dysplasia in the 7MM were found to be 17,058 cases in 2021. These cases are expected to increase by 2032 at a CAGR of 0.5% during the study period (2019–2032). The incident cases of BPD are derived from preterm population of <28 weeks.
  • Among 7MM, the United States has the highest incident cases of Bronchopulmonary Dysplasia with 13,222 cases in 2021. 
  • Assessments as per DelveInsight’s analysts show that the majority of cases of Bronchopulmonary Dysplasia are in ≤750 g birth weight preterm infants as compared to other birth-weight groups. In the United States, there were 5,203 cases of Bronchopulmonary Dysplasia in ≤750 g birth weight group preterm infants followed by 751-1000 g (5,022 cases), 1001-1250 g (2,290 cases), and ≥1250 g (706 cases) in 2021. These cases are expected to increase by 2032.
  • The severity‚Äźspecific data reveal the highest number of preterm infants are having mild Bronchopulmonary Dysplasia.
  • In the United States, there were a total of 5,210, 5,192, and 2,820 severity-specific cases of mild, moderate, and severe Bronchopulmonary Dysplasia respectively, in 2021. As per DelveInsight’s analysts, the severity-specific cases of Bronchopulmonary Dysplasia will increase by 2032.
  • In EU-5, Germany has the highest number of cases of Bronchopulmonary Dysplasia with 944 cases in 2021, followed by France with 931 cases and the United Kingdom with 735 cases. While Italy has the least number of cases with 386 in 2021.
  • In 2021, Japan had 452 incident cases of Bronchopulmonary Dysplasia.

Scope of the Report

  • The report covers the descriptive overview of Bronchopulmonary Dysplasia, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden of Bronchopulmonary Dysplasia.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM, a total number of incident cases of Bronchopulmonary Dysplasia, weight-specific cases of Bronchopulmonary Dysplasia, and severity-specific cases of Bronchopulmonary Dysplasia.

 Report Highlights

  • 11-Year Forecast of Bronchopulmonary Dysplasia
  • 7MM Coverage 
  • Total incident cases of Bronchopulmonary Dysplasia
  • Weight-specific Cases of Bronchopulmonary Dysplasia
  • Severity-specific Cases of Bronchopulmonary Dysplasia

Key Questions Answered

  • What are the disease risk and burdens of Bronchopulmonary Dysplasia?
  • What is the historical Bronchopulmonary Dysplasia patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Bronchopulmonary Dysplasia at the 7MM level?
  • What will be the growth opportunities across the 7MM concerning the patient population about Bronchopulmonary Dysplasia?
  • Out of the above-mentioned countries, which country would have the highest incident population of Bronchopulmonary Dysplasia during the forecast period (2022–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

Reasons to buy

The Bronchopulmonary Dysplasia report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Bronchopulmonary Dysplasia epidemiology forecast.
  • The Bronchopulmonary Dysplasia epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Bronchopulmonary Dysplasia epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation 
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Bronchopulmonary Dysplasia Patient Overview at a Glance

3.1. Patient Share (%) Distribution of Bronchopulmonary Dysplasia in 2019

3.2. Patient Share (%) Distribution of Bronchopulmonary Dysplasia in 2032

4. Executive Summary of Bronchopulmonary Dysplasia

5. Disease Background and Overview

5.1. Introduction of Bronchopulmonary Dysplasia

5.2. Classification of Bronchopulmonary Dysplasia

5.3. Signs and Symptoms of Bronchopulmonary Dysplasia

5.4. Etiology associated with Bronchopulmonary Dysplasia

5.5. Pathophysiology of Bronchopulmonary Dysplasia

5.6. Diagnosis of Bronchopulmonary Dysplasia

5.7. Biomarkers for Bronchopulmonary Dysplasia

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Methodology of Epidemiology

6.3. Assumptions and Rationale: 7MM

6.3.1. The United States

6.3.2. The Five European Countries (Germany, France, Italy, Spain, and the United Kingdom)

6.3.3. Japan

6.4. Total Incident Cases of Bronchopulmonary Dysplasia in the 7MM

6.5. The United States

6.5.1. Incident Cases of Bronchopulmonary Dysplasia in the United States

6.5.2. Weight-specific Cases of Bronchopulmonary Dysplasia in the United States

6.5.3. Severity-specific Cases of Bronchopulmonary Dysplasia in the United States

6.6. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)

6.6.1. Germany

6.6.1.1. Incident Cases of Bronchopulmonary Dysplasia in Germany

6.6.1.2. Weight-specific Cases of Bronchopulmonary Dysplasia in Germany

6.6.1.3. Severity-specific Cases of Bronchopulmonary Dysplasia in Germany

6.6.2. France

6.6.2.1. Incident Cases of Bronchopulmonary Dysplasia in France

6.6.2.2. Weight-specific Cases of Bronchopulmonary Dysplasia in France

6.6.2.3. Severity-specific Cases of Bronchopulmonary Dysplasia in France

6.6.3. Italy

6.6.3.1. Incident Cases of Bronchopulmonary Dysplasia in Italy

6.6.3.2. Weight-specific Cases of Bronchopulmonary Dysplasia in Italy

6.6.3.3. Severity-specific Cases of Bronchopulmonary Dysplasia in Italy

6.6.4. Spain

6.6.4.1. Incident Cases of Bronchopulmonary Dysplasia in Spain

6.6.4.2. Weight-specific Cases of Bronchopulmonary Dysplasia in Spain

6.6.4.3. Severity-specific Cases of Bronchopulmonary Dysplasia in Spain

6.6.5. The United Kingdom

6.6.5.1. Incident Cases of Bronchopulmonary Dysplasia in the UK

6.6.5.2. Weight-specific Cases of Bronchopulmonary Dysplasia in the UK

6.6.5.3. Severity-specific Cases of Bronchopulmonary Dysplasia in the UK

6.7. Japan

6.7.1. Incident Cases of Bronchopulmonary Dysplasia in Japan

6.7.2. Weight-specific Cases of Bronchopulmonary Dysplasia in Japan

6.7.3. Severity-specific Cases of Bronchopulmonary Dysplasia in Japan

7. Patient Journey

8. KOL Views

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Tables

Table 1: Summary of Bronchopulmonary Dysplasia Epidemiology (2019–2032)

Table 2: Incident Cases of Bronchopulmonary Dysplasia in the 7MM (2019–2032)

Table 3: Incident Cases of Bronchopulmonary Dysplasia in the US (2019–2032)

Table 4: Weight-specific Cases of Bronchopulmonary Dysplasia in the US (2019–2032)

Table 5: Severity-specific Cases of Bronchopulmonary Dysplasia in the US (2019–2032)

Table 6: Incident Cases of Bronchopulmonary Dysplasia in Germany (2019–2032)

Table 7: Weight-specific Incident Cases of Bronchopulmonary Dysplasia in Germany (2019–2032)

Table 8: Severity-specific Incident Cases of Bronchopulmonary Dysplasia in Germany (2019–2032)

Table 9: Incident Cases of Bronchopulmonary Dysplasia in France (2019–2032)

Table 10: Weight-specific Incident Cases of Bronchopulmonary Dysplasia in France (2019–2032)

Table 11: Severity-specific Incident Cases of Bronchopulmonary Dysplasia in France (2019–2032)

Table 12: Incident Cases of Bronchopulmonary Dysplasia in Italy (2019–2032)

Table 13: Weight-specific Incident Cases of Bronchopulmonary Dysplasia in Italy (2019–2032)

Table 14: Severity-specific Incident Cases of Bronchopulmonary Dysplasia in Italy (2019–2032)

Table 15: Incident Cases of Bronchopulmonary Dysplasia in Spain (2019–2032)

Table 16: Weight-specific Incident Cases of Bronchopulmonary Dysplasia in Spain (2019–2032)

Table 17: Severity-specific Incident Cases of Bronchopulmonary Dysplasia in Spain (2019–2032)

Table 18: Incident Cases of Bronchopulmonary Dysplasia in the UK (2019–2032)

Table 19: Weight-specific Incident Cases of Bronchopulmonary Dysplasia in the UK (2019–2032)

Table 20: Severity-specific Incident Cases of Bronchopulmonary Dysplasia in the UK (2019–2032)

Table 21: Incident Cases of Bronchopulmonary Dysplasia in Japan (2019–2032)

Table 22: Weight-specific Cases of Bronchopulmonary Dysplasia in Japan (2019–2032)

Table 23: Severity-specific Cases of Bronchopulmonary Dysplasia in Japan (2019–2032)

List of Figures

Figure 1: Factors influencing Bronchopulmonary Dysplasia

Figure 2: Classification of Bronchopulmonary Dysplasia

Figure 3: Signs and Symptoms of Bronchopulmonary Dysplasia

Figure 4: Risk Factors of Bronchopulmonary Dysplasia

Figure 5: Stages of Lung Development

Figure 6: Pathogenesis of Bronchopulmonary Dysplasia

Figure 7: Diagnosis of Bronchopulmonary Dysplasia

Figure 8: Biomarkers Associated with Bronchopulmonary Dysplasia

Figure 9: Incident Cases of Bronchopulmonary Dysplasia in the 7MM (2019–2032)

Figure 10: Incident Cases of Bronchopulmonary Dysplasia in the US (2019–2032)

Figure 11: Weight-specific Cases of Bronchopulmonary Dysplasia in the US (2019–2032)

Figure 12: Severity-specific Cases of Bronchopulmonary Dysplasia in the US (2019–2032)

Figure 13: Incident Cases of Bronchopulmonary Dysplasia in Germany (2019–2032)

Figure 14: Weight-specific Cases of Bronchopulmonary Dysplasia in Germany (2019–2032)

Figure 15: Severity-specific Cases of Bronchopulmonary Dysplasia in Germany (2019–2032)

Figure 16: Incident Cases of Bronchopulmonary Dysplasia in France (2019–2032)

Figure 17: Weight-specific Cases of Bronchopulmonary Dysplasia in France  (2019–2032)

Figure 18: Severity-specific Cases of Bronchopulmonary Dysplasia in France  (2019–2032)

Figure 19: Incident Cases of Bronchopulmonary Dysplasia in Italy (2019–2032)

Figure 20: Weight-specific Cases of Bronchopulmonary Dysplasia in Italy (2019–2032)

Figure 21: Severity-specific Cases of Bronchopulmonary Dysplasia in Italy (2019–2032)

Figure 22: Incident Cases of Bronchopulmonary Dysplasia in Spain (2019–2032)

Figure 23: Weight-specific Cases of Bronchopulmonary Dysplasia in Spain (2019–2032)

Figure 24: Severity-specific Cases of Bronchopulmonary Dysplasia in Spain (2019–2032)

Figure 25: Incident Cases of Bronchopulmonary Dysplasia in the UK (2019–2032)

Figure 26: Weight-specific Cases of Bronchopulmonary Dysplasia in the UK (2019–2032)

Figure 27: Severity-specific Cases of Bronchopulmonary Dysplasia in the UK (2019–2032)

Figure 28: Incident Cases of Bronchopulmonary Dysplasia in Japan (2019–2032)

Figure 29: Weight-specific Cases of Bronchopulmonary Dysplasia in Japan (2019–2032)

Figure 30: Severity-specific Cases of Bronchopulmonary Dysplasia in Japan (2019–2032)

Figure 31: Patient Journey

Forward to Friend

Need A Quote